Last reviewed · How we verify
Topical TXA
At a glance
| Generic name | Topical TXA |
|---|---|
| Also known as | Topical Tranexamic acid, Topical TXA through drain, TXA |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement (PHASE4)
- Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma (PHASE2, PHASE3)
- "Topical Tranexamic Acid With Flap Fixation: A Novel Approach to Minimize Post-operative Drainage and Surgical Site Infection in Patients Undergoing Modified Radical Mastectomy" (NA)
- Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery (EARLY_PHASE1)
- Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery (PHASE4)
- Protest Trial: TXA vs Saline (PHASE3)
- A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery (PHASE4)
- Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical TXA CI brief — competitive landscape report
- Topical TXA updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI